Physician profile
Cesar J Aleman
NPI 1336172824
$3,696.75
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,813 · 2020: $878 · 2021: $674 · 2022: $332.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $937.13 | 2019-2021 | |
| Novo Nordisk INC | $665.60 | 2019-2022 | |
| Amarin Pharma, INC. | $450.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $432.81 | 2019-2022 | |
| Lilly USA, LLC | $360.25 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.53 | 2019-2022 | |
| Genzyme Corporation | $180.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $82.34 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $52.87 | 2019-2022 | |
| Amgen INC. | $49.59 | 2021-2022 | |
| Abbvie INC. | $49.50 | 2021 | |
| Merck Sharp & Dohme LLC | $44.89 | 2020-2021 | |
| Mylan Specialty L.P. | $36.73 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $31.31 | 2019-2020 | |
| Allergan, INC. | $19.31 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $15.88 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Aleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.